Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PM 8002

Next Previous
Drug Profile

PM 8002

Alternative Names: BNT-327; PM-8002

Latest Information Update: 19 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotheus
  • Developer BioNTech; Biotheus; Duality Biologics; Genmab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer; Triple negative breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Liver cancer; Malignant-mesothelioma; Neuroendocrine tumours; Solid tumours
  • Phase I/II Colorectal cancer; HER2 positive breast cancer; Lung cancer

Most Recent Events

  • 15 Sep 2025 BioNTech SE plans a phase III trial for HER2-negative breast cancer (First-line therapy, Metastatic diseases, Combination therapy,Inoperable/unresectable) and Triple-negative breast cancer (First-line therapy, Metastatic diseases, Combination therapy,Inoperable/unresectable) in October 2025 (IV) (NCT07173751)
  • 31 Aug 2025 Biotheus plans a phase II trial for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease, Inoperable/Unresectable) in China (IV, Infusion) in August 2025 (NCT07133750)
  • 08 Aug 2025 BioNTech SE plans to initiate a phase Ib/II trial for Non-small Cell Lung Cancer (Late-stage disease, In combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) (IV) (NCT07111520)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top